FDA Warning Letter Could Hamper Zhejiang Medicine’s US Foray
A recent US FDA warning letter could affect efforts by major Chinese API firm Zhejiang Medicine to build its US business, amid falling North American exports from China and a string of similar warnings over the past few years. But efforts are being made both by Chinese manufacturers and by US and Chinese regulators to ensure adherence to international standards.
You may also be interested in...
HIV drug Tivicay is expected to become cheaper in China under a recent manufacturing deal between ViiV and Desano. The Chinese firm expects to gain a 35% share of the global generic antiretroviral API supply market this year after patent licensing agreements with the Medicines Patent Pool.
In a rare public speech, China FDA commissioner Bi Jingquan has called for improved drug quality and an ecosystem to reward high quality medicines, highlighting the agency’s drive to step up enforcement amid another recent scandal that has revealed broad quality problems.
Rather than reviving its own IPO plans, U.S. bioventure Ambrx has turned to a consortium of Chinese investors to secure its future via an acquisition deal that will provide funding for its pipeline and facilitate access to a large market and new partners.